Drug intelligence / Profile preview

PEV-001

Development stage: Unknown
Lead developer: POSVAX
Modality: Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

PEV-001 is a placebo control formulation developed by POSVAX for use in clinical trials of its 9-valent human papillomavirus (HPV) vaccine candidate, PV-001. It contains the adjuvant aluminum phosphate but lacks the viral antigens (HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58) present in the active vaccine. PEV-001 is used in Phase 1 clinical studies to evaluate the safety and immunogenicity of PV-001 in healthy adult women by providing a comparative baseline against which the active vaccine's effects can be measured.

Beyond the preview

Go deeper on PEV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEV-001.

Explore the full profile